• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

    Read More
  • image

    Developing precision therapies

    for type 1 diabetes

    VIDEO
  • image

    Intralymphatic immunotherapy

    with Diamyd®

    VIDEO

Press Releases 

Events & Mediawatch 

 July 9, 2024   Sweden
 June 27, 2024   Sweden
 June 17, 2024   USA
 June 14, 2024   USA
 June 5, 2024   Sweden

Company Presentation

 June 28, 2024
Download PDF

The upcoming interim analysis is a significant milestone. It will provide insights into the progression of DIAGNODE-3, specifically informing whether the trial is still on track to reach its key endpoints.

image Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 3 23/24

Calendar

 Dates for financial information and other events
September 9 − September 13, 2024
EASD 2024
October 9, 2024
Year-End Report
Year-End Report 2023/2024
October 16 − October 19, 2024
ISPAD 2024
November 4 − November 8, 2024
IDS 2024
November 14, 2024
Annual Report
Annual Report 2023/2024
December 5, 2024
Annual General Meeting
Annual General Meeting 2023/2024

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop type 1 diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in type 1 diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board

Manufacturing of GAD65 in Umeå

Image
A new facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden. The primary purpose is the manufacture of recombinant GAD65, the active pharmaceutical ingredient in the investigational medicine Diamyd®, an antigen-specific immunotherapy currently in late-stage clinical development.

Diamyd Medical has chosen Cytiva’s FlexFactory, a configurable single-use bioprocess platform for the manufacturing process that is based on a baculovirus-insect cell expression system.
Read More

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)


Read More

Order GAD for preclinical research

ORDER

Annual Report

  November 29, 2023
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Box 7349, SE-103 90 Stockholm
Visiting addresses:
Kungsgatan 29, SE-111 56 Stockholm
+46 8 661 00 26
Umeå:
Formvägen 7B, SE-906 21 Umeå

Subscribe

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research